{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:42:55Z","timestamp":1773189775326,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"On-X Life Technologies, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>To assess if warfarin targeted to international normalized ratio (INR) 1.8 (range 1.5\u20132.0) is safe for all patients with an On-X aortic mechanical valve.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This prospective, observational registry follows patients receiving warfarin targeted at an INR of 1.8 (range 1.5\u20132.0) plus daily aspirin (75\u2013100\u2009mg) after On-X aortic valve replacement. The primary end point is a composite of thromboembolism, valve thrombosis and major bleeding. Secondary end points include the individual rates of thromboembolism, valve thrombosis and major bleeding, as well as the composite in subgroups of home or clinic-monitored INR and risk categorization for thromboembolism. The control was the patient group randomized to standard-dose warfarin (INR 2.0\u20133.0) plus daily aspirin 81\u2009mg from the PROACT trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 510 patients were enroled at 23 centres in the UK, USA and Canada. Currently, the median follow-up duration is 3.4\u2009years, and median achieved INR is 1.9. The primary composite end point rate in the low INR patients is 2.31% vs 5.39% (95% confidence interval 4.12\u20136.93%) per patient-year in the PROACT control group, constituting a 57% reduction. Results are consistent in subgroups of home or clinic-monitored, and high-risk patients, with reductions of 56%, 57% and 57%, respectively. Major and total bleeding are decreased by 85% and 73%, respectively, with similar rates of thromboembolic events. No valve thrombosis occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Interim results suggest that warfarin targeted at an INR of 1.8 (range 1.5\u20132.0) plus aspirin is safe and effective in patients with an On-X aortic mechanical valve with or without home INR monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezae117","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:30:24Z","timestamp":1713227424000},"source":"Crossref","is-referenced-by-count":9,"title":["On-X aortic valve replacement patients treated with low-dose warfarin and low-dose aspirin"],"prefix":"10.1093","volume":"65","author":[{"given":"Aung Y","family":"Oo","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Bart\u2019s Health NHS Trust , London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Loubani","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Hull University Teaching Hospitals NHS Trust , Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc W","family":"Gerdisch","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Franciscan Health , Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Zacharias","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Blackpool Teaching Hospitals Foundation Trust , Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey M","family":"Tsang","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Southampton General Hospital , Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Perchinsky","sequence":"additional","affiliation":[{"name":"Department of Surgery, Royal Jubilee Hospital , Victoria, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Carl","family":"Hagberg","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Hartford Hospital , Hartford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Surgery, Virginia Tech Carilion School of Medicine , Roanoke, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohanakrishnan","family":"Sathyamoorthy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Burnett School of Medicine at TCU , Fort Worth, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024052919154693600_ezae117-B1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation"},{"key":"2024052919154693600_ezae117-B2","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2024052919154693600_ezae117-B3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"2024052919154693600_ezae117-B4","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2018.03.535","article-title":"Anticoagulation and antiplatelet strategies after On-X mechanical aortic valve replacement","volume":"71","author":"Puskas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024052919154693600_ezae117-B5","doi-asserted-by":"crossref","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"2024052919154693600_ezae117-B6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ejcts\/ezab389","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"60","author":"Vahanian","year":"2021","journal-title":"Eur J Cardiothorac Surg"},{"key":"2024052919154693600_ezae117-B7","author":"Artivion"},{"key":"2024052919154693600_ezae117-B8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jtcvs.2014.01.004","article-title":"Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial","volume":"147","author":"Puskas","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024052919154693600_ezae117-B9"},{"key":"2024052919154693600_ezae117-B10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejcts.2007.12.055","article-title":"Guidelines for reporting mortality and morbidity after cardiac valve interventions","volume":"33","author":"Akins","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"2024052919154693600_ezae117-B11","author":"SAS","year":"2013"},{"key":"2024052919154693600_ezae117-B12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ahj.2010.05.005","article-title":"LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the \u201cLOWERING-IT\u201d Trial","volume":"160","author":"Torella","year":"2010","journal-title":"Am Heart J"},{"key":"2024052919154693600_ezae117-B13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/eurheartj\/ehu330","article-title":"Telemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants","volume":"36","author":"Koertke","year":"2015","journal-title":"Eur Heart J"},{"key":"2024052919154693600_ezae117-B14","first-page":"CD003839","article-title":"Self-monitoring and self-management of oral anticoagulation","volume":"7","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezae117\/57237888\/ezae117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezae117\/57986671\/ezae117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezae117\/57986671\/ezae117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T19:16:03Z","timestamp":1717010163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezae117\/7646070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezae117","relation":{},"ISSN":["1873-734X"],"issn-type":[{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,4,15]]},"article-number":"ezae117"}}